Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 11Gastrointestinal 6Other 4Lymphoid 4Dermatologic 4Genitourinary 3Thoracic 2Other hematologic neoplasm 2Plasma cell 1Other neoplasm 1Head & Neck 1CNS 1

Conditions

Melanoma 3Skin Neoplasms 1Dermatitis, Contact 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Docosahexaenoic Acids × Dermatologic × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00087776 2025-07-23

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

American Regent, Inc.

Phase 3 Terminated
393 enrolled
Dermatologic

Melanoma

NCT01032343 2013-08-22

An Immunonutritional Approach to the Prevention of Skin Cancer

University of Manchester

Phase NA Completed
90 enrolled
Dermatologic

Dermatitis, Contact, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡